All In Biotech

Drug Trial Radar · NCT06343714

A Study of FB1003 in Healthy and Osteoarthritis Pain Subjects

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Escalating Single and Multiple Doses of FB1003 in the Healthy and Osteoarthritis Pain Subjects

Last checked: Nov 20, 2026Latest source record: Jun 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

64

Planned (sponsor's estimate)

Start

Apr 7, 2024

Primary completion

Feb 28, 2026

Study completion May 30, 2026

Sponsor

Lead sponsor
4B Technologies LimitedIndustry
Sponsor type
Industry
First posted
Apr 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of Part 1 is to evaluate safety and tolerability of FB1003 when given subcutaneously to healthy participants. Blood tests will be done to examine blood exposure, concentration and half-life of FB1003 following administrations. For each participant, the study will last up to about 12 weeks for single ascending dose part, and 18 weeks for multiple ascending dose part, including screening. The purpose of Part 2 is to assess the safety, tolerability, PK and efficacy of SAD of SC administered FB1003 in adult subjects with osteoarthritis (OA) pain.

Conditions

  • Healthy Volunteers

Interventions

  • FB1003Drug

    Subcutaneous (SC) injection

  • PlaceboDrug

    Subcutaneous (SC) injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary endpoint in the study is the incidence and severity of treatment emergent adverse events (TEAEs) in participants treated with FB1003 or placebo.Time frame: Baseline to end of study, SAD up to 56 days and MAD up to 84 days.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network

    Brisbane, Queensland, Australia · Completed

  • Veritus Research

    Bayswater, Victoria, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.